Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer ( PFE 0.22%) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many income investors, questions about the sustainability of the dividend persist.

Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally ...